Danish jewellery maker
Pandora on Tuesday raised its full-year revenue
outlook as it reported second-quarter sales above analyst
forecasts. Pandora said it now expected organic sales. -Today at 01:37 am- MarketScreener
Novo Nordisk hopes to show additional health benefits from taking its hugely popular drug Wegovy, apart from losing weight and cutting the risk of heart disease, says executive.
Novo Nordisk hikes FY outlook as demand for weight-loss drug Wegovy soars reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
COPENHAGEN (Reuters) -Novo Nordisk's limits on U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug will last into next year even as the Danish drugmaker spends billions boosting output, its CEO told Reuters on Thursday. Demand for Wegovy will be very high for the foreseeable future and higher than the Danish drugmaker can supply, Lars Fruergaard Jorgensen said in an interview after the company raised its full-year financial forecasts. Earlier on Thursday, the company said it would continue to restrict U.S. supplies of starter doses of Wegovy as the company struggles to keep up with soaring demand.